SubsidieMeestersLIACFLASH: a life changing IOeRT technology for oncology care
LIACFLASH is an innovative IOeRT system leveraging the FLASH effect to deliver high radiation doses that effectively target tumors while minimizing damage to surrounding healthy tissue.
Projectdetails
Introduction
Radiation Therapy is, along with surgery, the most effective therapeutic approach for the treatment of solid tumours.
Challenges in Radiation Therapy
Unfortunately, biological effects of radiation dose to healthy organs at risk (often surrounding targeted tumour mass) represent a major dose-limiting constraint in Radiation Therapy. This implies that tumours cannot always be successfully treated, as delivered dose might not be enough for an effective treatment, decreasing survival of these cancer patients.
LIACFLASH System
LIACFLASH is an IOeRT system for cancer treatment built on a breakthrough scientific discovery: the FLASH effect.
Benefits of the FLASH Effect
The FLASH effect enables:
- Delivery of high radiation dose
- Significantly reduced associated radiocytotoxicity
- Efficient tumour killing
This advancement widens the therapeutic window.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.962 |
| Totale projectbegroting | € 3.571.375 |
Tijdlijn
| Startdatum | 1-12-2022 |
| Einddatum | 31-5-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- S.I.T. - SORDINA IORT TECHNOLOGIES SPApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’BetaGlue's BAT-90 is a personalized radiotherapy platform that targets solid tumors like HCC and PDAC, minimizing off-target effects through percutaneous administration, showing promising safety and effectiveness. | EIC Accelerator | € 2.499.999 | 2024 | Details |
LILY: A Breakthrough Technology to Prevent Chemotherapy-Induced Hair LossLILY is a portable device that prevents chemotherapy-induced hair loss by using localized microvasculature compression therapy to inhibit drug delivery to hair follicles. | EIC Accelerator | € 2.499.999 | 2023 | Details |
IntraVenous Immune BoostHEPHAISTOS-Pharma's ONCO-Boost is a groundbreaking intravenous TLR4 immunostimulant aimed at treating metastatic cancers, potentially curing 10x more patients than current therapies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’
BetaGlue's BAT-90 is a personalized radiotherapy platform that targets solid tumors like HCC and PDAC, minimizing off-target effects through percutaneous administration, showing promising safety and effectiveness.
LILY: A Breakthrough Technology to Prevent Chemotherapy-Induced Hair Loss
LILY is a portable device that prevents chemotherapy-induced hair loss by using localized microvasculature compression therapy to inhibit drug delivery to hair follicles.
IntraVenous Immune Boost
HEPHAISTOS-Pharma's ONCO-Boost is a groundbreaking intravenous TLR4 immunostimulant aimed at treating metastatic cancers, potentially curing 10x more patients than current therapies.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Treatment planning assessment for the Optiflux radiosurgery systemDit project ontwikkelt een innovatieve radiotherapie met sub-MeV X-stralen voor nauwkeurige tumorbehandeling en minder schade aan omliggende organen. | Mkb-innovati... | € 20.000 | 2021 | Details |
Targeted nanohorns for lithium neutron capture therapyTARLIT aims to enhance neutron capture therapy for cancer by using nanoparticles to deliver enriched lithium compounds, improving treatment precision and efficacy against tumors. | ERC Proof of... | € 150.000 | 2023 | Details |
The first AI-guided toxicity atlas for safer and more effective abdominal radiation therapyThe AIDose project aims to create a 3D toxicity risk atlas for thoracic and abdominal organs using AI to enhance radiotherapy planning and reduce treatment-related toxicities in cancer patients. | ERC Consolid... | € 1.999.972 | 2025 | Details |
Next Generation Glioma Treatments using Direct Light TherapyGlioLighT aims to revolutionize glioma treatment by developing Direct Light Therapy (DLT) for targeted ROS generation, enhancing efficacy and safety while eliminating the need for toxic photosensitisers. | EIC Pathfinder | € 2.219.087 | 2024 | Details |
Single crystal diffraction assessment for the Optiflux radiosurgery systemDit project ontwikkelt een innovatieve radiotherapie met sub-MeV X-stralen voor nauwkeurige tumorbehandeling en minder schade aan omliggende organen. | Mkb-innovati... | € 20.000 | 2021 | Details |
Treatment planning assessment for the Optiflux radiosurgery system
Dit project ontwikkelt een innovatieve radiotherapie met sub-MeV X-stralen voor nauwkeurige tumorbehandeling en minder schade aan omliggende organen.
Targeted nanohorns for lithium neutron capture therapy
TARLIT aims to enhance neutron capture therapy for cancer by using nanoparticles to deliver enriched lithium compounds, improving treatment precision and efficacy against tumors.
The first AI-guided toxicity atlas for safer and more effective abdominal radiation therapy
The AIDose project aims to create a 3D toxicity risk atlas for thoracic and abdominal organs using AI to enhance radiotherapy planning and reduce treatment-related toxicities in cancer patients.
Next Generation Glioma Treatments using Direct Light Therapy
GlioLighT aims to revolutionize glioma treatment by developing Direct Light Therapy (DLT) for targeted ROS generation, enhancing efficacy and safety while eliminating the need for toxic photosensitisers.
Single crystal diffraction assessment for the Optiflux radiosurgery system
Dit project ontwikkelt een innovatieve radiotherapie met sub-MeV X-stralen voor nauwkeurige tumorbehandeling en minder schade aan omliggende organen.